Journal of the American Academy of Dermatology
Volume 56, Issue 4 , Pages 710-712 , April 2007

Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis

  • Whitney A. High, MD, M Eng

      Affiliations

    • Dermatology and Pathology, University of Colorado Health Sciences Center, Denver
    • Corresponding Author InformationReprint requests: Whitney A. High, MD, M Eng, Dermatology and Pathology, University of Colorado Health Sciences Center, PO Box 6510, Mail Stop F703, Aurora, CO 80045-0510
    • ,
  • Reed A. Ayers, PhD

      Affiliations

    • Materials Science (Biomaterials), Colorado School of Mines, Golden
    • ,
  • Shawn E. Cowper, MD

      Affiliations

    • Dermatology and Pathology, Yale University Medical Center, New Haven, Connecticut

References 

  1. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:21–26
  2. White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol. 2006;41:272–278
  3. Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol. 2006;20:563–576
  4. Center for Drug Evaluation and Research. US Food and Drug Administration World Wide Web site. Public health advisory: public health advisory update on magnetic resonance imaging (MRI) contrast agents containing gadolinium and nephrogenic fibrosing dermopathy (December 22, 2006). Available from: URL:http://www.fda.gov/cder/drug/advisory/gadolinium_agents.htm. Accessed December 30, 2006.

PII: S0190-9622(07)00207-1

doi: 10.1016/j.jaad.2007.01.022

Journal of the American Academy of Dermatology
Volume 56, Issue 4 , Pages 710-712 , April 2007

Article Tools